Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1337-1349

  Sagnelli, Evangelista ^a   Pisaturo, Mariantonietta ^b   Martini, Salvatore ^a   Sagnelli, Caterina ^a   Filippini, Pietro ^a   Coppola, Nicola ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Division of Infectious Diseases   (Italy)

Author keywords

Hepatitis B virus hepatitis C virus coinfection; Hepatitis B virus hepatitis C virus coinfection treatment; Hepatitis B virus hepatitis C virus epidemiology; Hepatitis B virus hepatitis C virus HIV interaction

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; PEGINTERFERON; RIBAVIRIN; TENOFOVIR; VIRUS DNA; VIRUS RNA; ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BOCEPREVIR; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TELBIVUDINE;

COMORBIDITY; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; REVIEW; VIRUS REPLICATION; ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL FEATURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; VIRUS REACTIVATION;

HEPATITIS B VIRUS/HEPATITIS C VIRUS COINFECTION; HEPATITIS B VIRUS/HEPATITIS C VIRUS COINFECTION TREATMENT; HEPATITIS B VIRUS/HEPATITIS C VIRUS EPIDEMIOLOGY; HEPATITIS B VIRUS/HEPATITIS C VIRUS/HIV INTERACTION;

ADENINE; ANTIVIRAL AGENTS; COINFECTION; DNA, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; RIBAVIRIN; RNA, VIRAL; VIRUS REPLICATION;

EID: 84902292538     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.913571     Document Type: Review

References (128)

1. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101-8
2. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-50
3. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33
4. Tsai JF, Jeng JE, Chang WY, et al. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1994;29(6):550-2
5. Chen DS, Kuo GC, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162(4):817-22
6. Crespo J, Lozano JL, de la CF, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994;89:1147-51
7. Coppola N, Pisapia R, Tonziello G, et al. Virological pattern in three compartments (plasma, PBMC and liver tissue) and clinical outcome in chronic HBV/HCV coinfection. Antivir Ther 2008;13:307-18
8. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999;30:257-64
9. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003;39:1036-41
10. Fattovich G, Tagger A, Brollo L, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991;163:400-2
11. Sagnelli E, Stroffolini T, Mele A, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol 2012;18(14):1616-21
12. Ohkawa K, Hayashi N, Yuki N, et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol 1994;21:509-14
13. Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994;21:159-66
14. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001;16:636-40
15. Semnani S, Roshandel G, Abdolahi N, et al. Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol 2007;18:20-1
16. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010;51:759-66
17. McQuillan GM, Kruszon-Moran D, Kottiri BJ, et al. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health 2004;94:1952-8
18. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62
19. Pallas JR, Farinas-Alvarez C, Prieto D, et al. Co-infections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999;15:699-704
20. Reddy GA, Dakshinamurthy KV, Neelaprasad P, et al. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 2005;23:41-3
21. Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
22. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005;79(9):1132-6
23. Kalinowska-Nowak A, Bociaga-Jasik M, Garlicki A, et al. Prevalence of hepatotropic viruses HBV and HCV in HIV-infected patients from Southern region of Poland. Acta Virologica 2000;44:23-8
24. Zhou J, Dore GJ, Zhang F, et al. TREAT Asia HIV Observational Database. Hepatitis B and C virus co-infection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol 2007;22:1510-18
25. Irshad M, Peter S. Spectrum of viral hepatitis in thalassemic children receiving multiple blood transfusions. Indian J Gastroenterol 2002;21:183-4
26. Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993;307:1095-7
27. Chu CM, Liaw YF. Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. Clin Infect Dis 1995;20(3):703-5
28. Coppola N, Marrocco C, Di Caprio D, et al. Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clin Infect Dis 2003;36:528-32
29. Chen SW, Lee TS, Hu CC, et al. Simultaneously acute hepatitis B virus and C virus coinfection and subsequent chronic hepatitis C. Scand J Infect Dis 2007;39(4):351-4
30. Yan BM, Lee SS. Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol 2005;19(12):729-30
31. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000;95(10):2978-80
32. Gruener NH, Jung MC, Ulsenheimer A, et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol 2002;37:866-9
33. Guido M, Rugge M, Colombari R, et al. Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Ital J Gastroenterol Hepatol 1998;30:414-17
34. Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002;36:1285-91
35. Wietzke P, Scott P, Braun F, et al. Clearance of HCVRNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 1999;19:348-53
36. Biliotti E, Kondili LA, Furlan C, et al. Acute hepatitis B in patients with or without underlying chronic HCV infection. J Infect 2008;57(2):152-7
37. Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009;49(4):1090-7
38. Chu CM, Yeh CT, Sheen IS, et al. Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV. Gut 2002;51(1):95-9
39. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126(4):1024-9
40. Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course J Clin Virol. 2006;35(3):317-20
41. Amin J, Dore GJ, O'Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community based linkage study. J Hepatol 2006;45:197-203
42. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442-8
43. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7
44. Weltman MD, Brotodihardjo A, Crewe EB, et al. Co-infection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45
45. Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991;265:1974-6
46. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347-54
47. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006;41(1):63-7
48. Schiavini M, Angeli E, Mainini A, et al. Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon 2011;11(7):525-31
49. Sagnelli C, Uberti-Foppa C, Pasquale G, et al. Liver histology in HIV/HCV coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases (PNAL). J Acquir Immune Defic Syndr 2010;54(3):338
50. Sagnelli C, Uberti-Foppa C, Pasquale G, et al. Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection. Infection 2013;41(5):959-67
51. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C, and Delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106-10
52. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010;51(3):759-66
53. Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
54. Pontisso P, Gerotto M, Ruvoletto MG, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol 1996;48(2):157-60
55. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 1998;36(7):2084-6
56. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34(2):404-10
57. Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206-17
58. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368(9539):938-45
59. Liaw YF, Chien RN, Lin SM, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17(8):449-52
60. Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96(10):2973-7
61. Potthoff A, Wedemeyer H, Boecher WO, et al. Hep-Net B/C Co-infection Study Group. The Hep-Net B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with with HBV/HCV co-infection. J Hepatol 2008;49(5):688-94
62. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006;43:100-7
63. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992;165:831-4
64. Zampino R, Marrone A, Merola A, et al. Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. J Med Virol 2009;81(12):2012-20
65. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49(4):652-7
66. Sagnelli E, Imparato M, Coppola N, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008;80:1547-53
67. Sagnelli E, Coppola N, Scolastico C, et al. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001;64:350-5
68. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-10
69. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006;106:1326-30
70. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006;20:1253-60
71. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11
72. Coppola N, Tonziello G, Pisaturo M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011;83:1909-16
73. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009;50(1):46-55
74. Brass V, Moradpour D. New insights into hepatitis B and C virus co-infection. J Hepatol 2009;51(3):423-5
75. Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009;51(3):446-57
76. Liu CJ, Liou JM, Chen DS, et al. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005;104:783-91
77. Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8
78. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12, 008 men in Taiwan. Am J Epidemiol 2003;157:674-82
79. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643-50
80. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
81. AASLD, IDSA Recommendations Managing, and Treating Hepatitis C. 2014. Available from: http://www. hcvguidelines.org
82. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61
83. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
84. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
85. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
86. Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferonalpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010;5:e13771
87. Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
88. Guo X, Yang G, Yuan J, et al. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. Plos One 2013;8(10):e77911
89. Lampertico P, Viganò M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon a-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62(2):290-8
90. Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11(3):285-300
91. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42
92. Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
93. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009;10:181-9
94. Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21(12):1391-404
95. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013.58(3):583-92. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/11/ WC500155469.pdf
96. Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of the a new Era. Rev Recent Clin Trials 2013. [Epub ahead of print]
97. Liu CJ, Chuang WL, Lee CM, et al. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009;136:496-504
98. Liu CJ, Chen PJ, Chen DS. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 2004;40:266
99. Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-33
100. Yu ML, Lee CM, Chen CL, et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013;57:2135-42
101. Liu CJ, Chu YT, Shau WY, et al. Treatment of patients with dual hepatitis C and B by peginterferon alfa and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014;63(3):506-14
102. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
103. Coppola N, Pisaturo M, Sagnelli C, et al. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. Plos One 2014;In Press
104. Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-76
105. Marrone A, Zampino R, D'Onofrio M, et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064-5
106. Yu ML, Lee CM, Chuang WL, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010;202(1):86-92
107. Yeh ML, Hung CH, Huang JF, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011;6:e20752
108. Coppola N, Stanzione M, Messina V, et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat 2012;19(12):890-6
109. Potthoff A, Berg T, Wedemeyer H. HEP-NET B/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009;44(12):1487-90
110. Yu JW, Sun LJ, Zhao YH, et al. Analysis of the efficacy of treatment with peginterferon a-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009;29(10):1485-93
111. Mart̀in-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-72
112. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006;57:815-18
113. Arribas JR, González-Garćia JJ, Lorenzo A, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005;19(13):1361-5
114. Puoti M, Torti C, Bruno R, et al. Natural history of chronic B in co-infected patients. J Hepatol 2006;44:S65-70
115. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004;38:S98-S103
116. Filippini P, Coppola N, Pisapia R, et al. Virological and clinical aspects of HBV-HCV coinfection in HIV-positive patients. J Med Virol 2007;79:1679-85
117. Maida I, Ŕios MJ, Pérez-Saleme L, et al. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. AIDS Res Hum Retroviruses 2008;24(5):679-83
118. Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 2009;51(5):574-81
119. Boyd A, Lacombe K, Miailhes P, et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010;17(1):65-76
120. Mandorfer M, Neukam K, Rivero A, et al. Strategies for assignment of HIV/HCV genotype 1-coinfected patients to either dual-therapy or direct-acting antiviral agent based triple therapy. Antivir Ther 2013. [Epub ahead of print]
121. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159(2):86-96
122. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597-605
123. Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013;207(Suppl 1):S26-32
124. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int 2013;33(Suppl 1):63-7
125. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142(6):1324-34
126. Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012;32(8):1194-9
127. Maćias J, Neukam K, Portilla J, et al. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. Dig Liver Dis 2013;45(Suppl 5):S355-62
128. Lazzarin A, Than S, Valluri SR, et al. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. HIV Clin Trials 2012;13(2):83-9